The presentation of new clinical data at a major conference often leads to increased investor interest and can positively impact the company's stock price in the short term. The data demonstrating sustained improvements and quality-of-life benefits directly relate to the potential success and adoption of TransCon PTH, which could lead to increased revenues and market share for Ascendis Pharma.